You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News items for the in vitro diagnostics industry for the week of Feb. 22, 2021.
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.
GenMark said its ePlex molecular diagnostic product revenue for Q4 was $45.4 million, an increase of 138 percent over the fourth quarter of 2019.
The company's nucleic acid extraction kits have offered labs relief from COVID-19-related shortages of traditional silica-based bind-wash-elute assays.
Investors responded to a report on Thursday that DiaSorin is considering the purchase of Luminex, one of its in vitro diagnostic testing competitors.
Oncocyte is now the sole shareholder of Razor, which developed the DetermaRx test that has now become the firm's flagship clinical offering.
For the 12 months ended Dec. 31, 2020, Biocartis' revenues rose to €43.1 million ($52.7 million) from €37.4 million in 2019.
The firm said its test eliminates the need for automated extraction systems in a high-volume PCR laboratory, reducing processing time, cost, and labor.
The company said it intends to pursue Emergency Use Authorization from the US Food and Drug Administration for the test and that it is planning an IPO.